Gut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not？

References

• Xin Yu J, Hubbard-Lucey VM, Tang J. Immuno-oncology drug development goes global. Nat Rev Drug Discov. 2019;18(12):899–900. PMID: 31780841. doi:10.1038/d41573-019-00167-9.
   Google Scholar
• Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018;17(12):854–855. PMID: 30482962. doi:10.1038/nrd.2018.210.
   Google Scholar
• Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–1492. PMID: 30361170. doi:10.1016/s1470-2045(18)30700-9.
   Google Scholar
• Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy. J Clin Med. 2019;8(10):1534. PMID: 31557787. doi:10.3390/jcm8101534.
   Google Scholar
• Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26. PMID: 28376884. doi:10.1186/s12929-017-0329-9.
   Google Scholar
• Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781–2789. PMID: 28609226. doi:10.1200/jco.2016.71.9476.
   Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. PMID: 29658845. doi:10.1056/NEJMoa1801946.
   Google Scholar
• Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. PMID: 28734759. doi:10.1016/s1470-2045(17)30422-9.
   Google Scholar
• Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. PMID: 30787022. doi:10.1158/1078-0432.CCR-18-4070.
   Google Scholar
• Cyriac G, Gandhi L. Emerging biomarkers for immune checkpoint inhibition in lung cancer. Semin Cancer Biol. 2018;52:269–277. PMID: 29782924. doi:10.1016/j.semcancer.2018.05.006.
   Google Scholar
• Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–1370. PMID: 29567708. doi:10.1126/science.aar6918.
   Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150. PMID: 30755690. doi:10.1038/s41568-019-0116-x.
   Google Scholar
• Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. Eur J Cancer. 2017;73:61–70. PMID: 28167454. doi:10.1016/j.ejca.2016.12.011.
   Google Scholar
• Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–3452. PMID: 27525433. doi:10.1172/jci87324.
   Google Scholar
• Balatoni T, Mohos A, Papp E, Sebestyen T, Liszkay G, Olah J, Varga A, Lengyel Z, Emri G, Gaudi I, et al. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunol Immunother. 2018;67(1):141–151. PMID: 28988380. doi:10.1007/s00262-017-2072-1.
   Google Scholar
• Owens B. Gut bacteria link to immunotherapy sparks interest. Nat Biotechnol. 2018;36(2):121. PMID: 29406499. doi:10.1038/nbt0218-121.
   Google Scholar
• Postler TS, Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metab. 2017;26(1):110–130. PMID: 28625867. doi:10.1016/j.cmet.2017.05.008.
   Google Scholar
• Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219–232. PMID: 28260787. doi:10.1038/nri.2017.7.
   Google Scholar
• Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104–108. PMID: 29302014. doi:10.1126/science.aao3290.
   Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103. PMID: 29097493. doi:10.1126/science.aan4236.
   Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. PMID: 29097494. doi:10.1126/science.aan3706.
   Google Scholar
• Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–1379. PMID: 28368458. doi:10.1093/annonc/mdx108.
   Google Scholar
• Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(1):10391. PMID: 26837003. doi:10.1038/ncomms10391.
   Google Scholar
• Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, Zheng H, Yao C, Wang Y, Lu S. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019;14(8):1378–1389. PMID: 31026576. doi:10.1016/j.jtho.2019.04.007.
   Google Scholar
• Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long H, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–1444. PMID: 29617710. doi:10.1093/annonc/mdy103.
   Google Scholar
• Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565(7741):600–605. PMID: 30675064. doi:10.1038/s41586-019-0878-z.
   Google Scholar
• Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. PMID: 27541692. doi:10.1371/journal.pbio.1002533.
   Google Scholar
• Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904. PMID: 20664075. doi:10.1152/physrev.00045.2009.
   Google Scholar
• Truong DT, Tett A, Pasolli E, Huttenhower C, Segata N. Microbial strain-level population structure and genetic diversity from metagenomes. Genome Res. 2017;27(4):626–638. PMID: 28167665. doi:10.1101/gr.216242.116.
   Google Scholar
• Thomas F, Hehemann JH, Rebuffet E, Czjzek M, Michel G. Environmental and gut bacteroidetes: the food connection. Front Microbiol. 2011;2:93. PMID: 21747801. doi:10.3389/fmicb.2011.00093.
   Google Scholar
• Heinken A, Thiele I, Drake HL. Anoxic conditions promote species-specific mutualism between gut microbes in silico. Appl Environ Microbiol. 2015;81(12):4049–4061. PMID: 25841013. doi:10.1128/AEM.00101-15.
   Google Scholar
• Litvak Y, Byndloss MX, Baumler AJ. Colonocyte metabolism shapes the gut microbiota. Science. 2018;362(6418):eaat9076. PMID: 30498100. doi:10.1126/science.aat9076.
   Google Scholar
• Vandeputte D, Kathagen G, D’Hoe K, Vieira-Silva S, Valles-Colomer M, Sabino J, Wang J, Tito RY, De Commer L, Darzi Y, et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature. 2017;551(7681):507–511. PMID: 29143816. doi:10.1038/nature24460.
   Google Scholar
• Johnson AJ, Vangay P, Al-Ghalith GA, Hillmann BM, Ward TL, Shields-Cutler RR, Kim AD, Shmagel AK, Syed AN, Walter J, et al. Daily sampling reveals personalized diet-microbiome associations in humans. Cell Host Microbe. 2019;25(6):789–802.e5. PMID: 31194939. doi:10.1016/j.chom.2019.05.005.
   Google Scholar
• Moeller AH, Li Y, Mpoudi Ngole E, Ahuka-Mundeke S, Lonsdorf EV, Pusey AE, Peeters M, Hahn BH, Ochman H. Rapid changes in the gut microbiome during human evolution. Proc Natl Acad Sci U S A. 2014;111(46):16431–16435. PMID: 25368157. doi:10.1073/pnas.1419136111.
   Google Scholar
• Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14(3):141–153. PMID: 24566914. doi:10.1038/nri3608.
   Google Scholar
• Cabinian A, Sinsimer D, Tang M, Jang Y, Choi B, Laouar Y, Laouar A. Gut symbiotic microbes imprint intestinal immune cells with the innate receptor SLAMF4 which contributes to gut immune protection against enteric pathogens. Gut. 2018;67(5):847–859. PMID: 28341747. doi:10.1136/gutjnl-2016-313214.
   Google Scholar
• Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016;352(6285):535–538. PMID: 27126035. doi:10.1126/science.aad9382.
   Google Scholar
• Grizotte-Lake M, Zhong G, Duncan K, Kirkwood J, Iyer N, Smolenski I, Isoherranen N, Vaishnava S. Commensals suppress intestinal epithelial cell retinoic acid synthesis to regulate Interleukin-22 activity and prevent microbial dysbiosis. Immunity. 2018;49(6):1103–15.e6. PMID: 30566883. doi:10.1016/j.immuni.2018.11.018.
   Google Scholar
• Palm NW, de Zoete MR, Flavell RA. Immune-microbiota interactions in health and disease. Clin Immunol. 2015;159(2):122–127. PMID: 26141651. doi:10.1016/j.clim.2015.05.014.
   Google Scholar
• Round JL, Palm NW. Causal effects of the microbiota on immune-mediated diseases. Sci Immunol. 2018;3(20):eaao1603. PMID: 29440265. doi:10.1126/sciimmunol.aao1603.
   Google Scholar
• Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105(24):1907–1911. PMID: 24316595. doi:10.1093/jnci/djt300.
   Google Scholar
• Shah MA. Gastric cancer: the gastric microbiota - bacterial diversity and implications. Nat Rev Gastroenterol Hepatol. 2017;14(12):692–693. PMID: 29042691. doi:10.1038/nrgastro.2017.140.
   Google Scholar
• Levy M, Blacher E, Elinav E. Microbiome, metabolites and host immunity. Curr Opin Microbiol. 2017;35:8–15. PMID: 27883933. doi:10.1016/j.mib.2016.10.003.
   Google Scholar
• Brown EM, Kenny DJ, Xavier RJ. Gut microbiota regulation of T cells during inflammation and autoimmunity. Annu Rev Immunol. 2019;37(1):599–624. PMID: 31026411. doi:10.1146/annurev-immunol-042718-041841.
   Google Scholar
• Pabst O, Slack E. IgA and the intestinal microbiota: the importance of being specific. Mucosal Immunol. 2019. PMID: 31740744. doi:10.1038/s41385-019-0227-4.
   Google Scholar
• Ko HJ, Chang SY. Regulation of intestinal immune system by dendritic cells. Immune Netw. 2015;15(1):1–8. PMID: 25713503. doi:10.4110/in.2015.15.1.1.
   Google Scholar
• Hua Y, Yang Y, Sun S, Lwanowycz S, Westwater C, Reizis B, Li Z, Liu B. Gut homeostasis and regulatory T cell induction depend on molecular chaperone gp96 in CD11c cells. Sci Rep. 2017;7(1):2171. PMID: 28526855. doi:10.1038/s41598-017-02415-7.
   Google Scholar
• Pandolfi F, Altamura S, Frosali S, Conti P. Key role of DAMP in inflammation, cancer, and tissue repair. Clin Ther. 2016;38(5):1017–1028. PMID: 27021609. doi:10.1016/j.clinthera.2016.02.028.
   Google Scholar
• Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines. 2013;12(3):285–295. PMID: 23496668. doi:10.1586/erv.13.22.
   Google Scholar
• Zegarra-Ruiz DF, El Beidaq A, Iniguez AJ, Lubrano Di Ricco M, Manfredo Vieira S, Ruff WE, Mubiru D, Fine RL, Sterpka J, Greiling TM, et al. A diet-sensitive commensal lactobacillus strain mediates TLR7-dependent systemic autoimmunity. Cell Host Microbe. 2019;25(1):113–27.e6. PMID: 30581114. doi:10.1016/j.chom.2018.11.009.
   Google Scholar
• Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–1089. PMID: 26541606. doi:10.1126/science.aac4255.
   Google Scholar
• Wu X, Tian Z. Gut-liver axis: gut microbiota in shaping hepatic innate immunity. Sci China Life Sci. 2017;60(11):1191–1196. PMID: 28840534. doi:10.1007/s11427-017-9128-3.
   Google Scholar
• Komban RJ, Stromberg A, Biram A, Cervin J, Lebrero-Fernandez C, Mabbott N, Yrlid U, Shulman Z, Bemark M, Lycke N. Activated Peyer’s patch B cells sample antigen directly from M cells in the subepithelial dome. Nat Commun. 2019;10(1):2423. PMID: 31160559. doi:10.1038/s41467-019-10144-w.
   Google Scholar
• Castro-Dopico T, Dennison TW, Ferdinand JR, Mathews RJ, Fleming A, Clift D, Stewart BJ, Jing C, Strongili K, Labzin LI, et al. Anti-commensal IgG drives intestinal inflammation and type 17 immunity in ulcerative colitis. Immunity. 2019;50(4):1099–114.e10. PMID: 30876876. doi:10.1016/j.immuni.2019.02.006.
   Google Scholar
• Marinelli L, Tenore GC, Novellino E. Probiotic species in the modulation of the anticancer immune response. Semin Cancer Biol. 2017;46:182–190. PMID: 28844794. doi:10.1016/j.semcancer.2017.08.007.
   Google Scholar
• Wang G, Yu Y, Wang YZ, Wang JJ, Guan R, Sun Y, Shi F, Gao J, Fu XL. Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy. J Cell Physiol. 2019;234(10):17023–17049. PMID: 30888065. doi:10.1002/jcp.28436.
   Google Scholar
• Cani PD. Microbiota and metabolites in metabolic diseases. Nat Rev Endocrinol. 2019;15(2):69–70. PMID: 30602737. doi:10.1038/s41574-018-0143-9.
   Google Scholar
• Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16(6):341–352. PMID: 27231050. doi:10.1038/nri.2016.42.
   Google Scholar
• Cheng HY, Ning MX, Chen DK, Ma WT. Interactions between the gut microbiota and the host innate immune response against pathogens. Front Immunol. 2019;10:607. PMID: 30984184. doi:10.3389/fimmu.2019.00607.
   Google Scholar
• Hegazy AN, West NR, Stubbington MJT, Wendt E, Suijker KIM, Datsi A, This S, Danne C, Campion S, Duncan SH, et al. Circulating and tissue-resident CD4 T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation. Gastroenterology. 2017;153(5):1320–37.e16. PMID: 28782508. doi:10.1053/j.gastro.2017.07.047.
   Google Scholar
• Mayor PC, Eng KH, Singel KL, Abrams SI, Odunsi K, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States immune deficiency network registry. J Allergy Clin Immunol. 2018;141(3):1028–1035. PMID: 28606585. doi:10.1016/j.jaci.2017.05.024.
   Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–167. PMID: 30523282. doi:10.1038/s41571-018-0142-8.
   Google Scholar
• Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178(4):795–806.e12. PMID: 31398337. doi:10.1016/j.cell.2019.07.008.
   Google Scholar
• Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6(1):8727. PMID: 26515465. doi:10.1038/ncomms9727.
   Google Scholar
• Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156–166. PMID: 30546113. doi:10.1038/s41579-018-0129-6.
   Google Scholar
• Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Lin YJ, Deng YF, Hsu WT, Wu CS, Li C. Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. 2018;8(1):158. PMID: 29317709. doi:10.1038/s41598-017-18596-0.
   Google Scholar
• Zhang C, Powell SE, Betel D, Shah MA. The gastric microbiome and its influence on gastric carcinogenesis: current knowledge and ongoing research. Hematol Oncol Clin North Am. 2017;31(3):389–408. PMID: 28501083. doi:10.1016/j.hoc.2017.01.002.
   Google Scholar
• Zhang C, Cleveland K, Schnoll-Sussman F, McClure B, Bigg M, Thakkar P, Schultz N, Shah MA, Betel D. Identification of low abundance microbiome in clinical samples using whole genome sequencing. Genome Biol. 2015;16(1):265. PMID: 26614063. doi:10.1186/s13059-015-0821-z.
   Google Scholar
• Riquelme E, Maitra A, McAllister F. Immunotherapy for pancreatic cancer: more than just a gut feeling. Cancer Discov. 2018;8(4):386–388. PMID: 29610286. doi:10.1158/2159-8290.Cd-18-0123.
   Google Scholar
• Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres LE, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403–416. PMID: 29567829. doi:10.1158/2159-8290.Cd-17-1134.
   Google Scholar
• Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immunotherapy. Cancer Lett. 2019;447:41–47. PMID: 30684593. doi:10.1016/j.canlet.2019.01.015.
   Google Scholar
• Mu Q, Tavella VJ, Luo XM. Role of lactobacillus reuteri in human health and diseases. Front Microbiol. 2018;9:757. PMID: 29725324. doi:10.3389/fmicb.2018.00757.
   Google Scholar
• He B, Hoang TK, Wang T, Ferris M, Taylor CM, Tian X, Luo M, Tran DQ, Zhou J, Tatevian N, et al. Resetting microbiota by lactobacillus reuteri inhibits T reg deficiency-induced autoimmunity via adenosine A2A receptors. J Exp Med. 2017;214(1):107–123. PMID: 27994068. doi:10.1084/jem.20160961.
   Google Scholar
• Liao PH, Kuo WW, Hsieh DJ, Yeh YL, Day CH, Chen YH, Chang SH, Padma VV, Chen YH, Huang CY. Heat-killed lactobacillus reuteri GMNL-263 prevents epididymal fat accumulation and cardiac injury in high-calorie diet-fed rats. Int J Med Sci. 2016;13(8):569–577. PMID: 27499689. doi:10.7150/ijms.15597.
   Google Scholar
• Cervantes-Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman J, Cortez VS, Caparon MG, Donia MS, Gilfillan S, et al. Lactobacillus reuteriinduces gut intraepithelial CD4+CD8αα+T cells. Science. 2017;357(6353):806–810. PMID: 28775213. doi:10.1126/science.aah5825.
   Google Scholar
• Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D’Angelo C, Massi-Benedetti C, Fallarino F, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–385. PMID: 23973224. doi:10.1016/j.immuni.2013.08.003.
   Google Scholar
• Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, Harrison O, Powrie F. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917–931. PMID: 23589566. doi:10.1084/jem.20122308.
   Google Scholar
• Jacouton E, Chain F, Sokol H, Langella P, Bermudez-Humaran LG. Probiotic strain lactobacillus casei BL23 prevents colitis-associated colorectal cancer. Front Immunol. 2017;8:1553. PMID: 29209314. doi:10.3389/fimmu.2017.01553.
   Google Scholar
• Maroof H, Hassan ZM, Mobarez AM, Mohamadabadi MA. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol. 2012;32(6):1353–1359. PMID: 22711009. doi:10.1007/s10875-012-9708-x.
   Google Scholar
• Yazdi MH, Mahdavi M, Kheradmand E, Shahverdi AR. The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. Arzneimittelforschung. 2012;62(11):525–531. PMID: 22945771. doi:10.1055/s-0032-1323700.
   Google Scholar
• Yazdi MH, Mahdavi M, Setayesh N, Esfandyar M, Shahverdi AR. Selenium nanoparticle-enriched lactobacillus brevis causes more efficient immune responses in vivo and reduces the liver metastasis in metastatic form of mouse breast cancer. Daru. 2013;21(1):33. PMID: 23631392. doi:10.1186/2008-2231-21-33.
   Google Scholar
• Riviere A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016;7:979. PMID: 27446020. doi:10.3389/fmicb.2016.00979.
   Google Scholar
• Ruiz L, Delgado S, Ruas-Madiedo P, Sanchez B, Margolles A. Bifidobacteria and their molecular communication with the immune system. Front Microbiol. 2017;8:2345. PMID: 29255450. doi:10.3389/fmicb.2017.02345.
   Google Scholar
• Wu BB, Yang Y, Xu X, Wang WP. Effects of Bifidobacterium supplementation on intestinal microbiota composition and the immune response in healthy infants. World J Pediatr. 2016;12(2):177–182. PMID: 25846071. doi:10.1007/s12519-015-0025-3.
   Google Scholar
• Tan TG, Sefik E, Geva-Zatorsky N, Kua L, Naskar D, Teng F, Pasman L, Ortiz-Lopez A, Jupp R, Wu HJ, et al. Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc Natl Acad Sci U S A. 2016;113(50):E8141–e50. PMID: 27911839. doi:10.1073/pnas.1617460113.
   Google Scholar
• Engevik MA, Luk B, Chang-Graham AL, Hall A, Herrmann B, Ruan W, Endres BT, Shi Z, Garey KW, Hyser JM, et al. Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways. MBio. 2019;10(3). PMID: 31213556. doi:10.1128/mBio.01087-19.
   Google Scholar
• Wang F, Yin Q, Chen L, Davis MM. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci U S A. 2018;115(1):157–161. PMID: 29255057. doi:10.1073/pnas.1712901115.
   Google Scholar
• Zitvogel L, Daillere R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017;15(8):465–478. PMID: 28529325. doi:10.1038/nrmicro.2017.44.
   Google Scholar
• Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol. 2008;74(5):1646–1648. PMID: 18083887. doi:10.1128/AEM.01226-07.
   Google Scholar
• Derrien M. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54(5):1469–1476. PMID: 15388697. doi:10.1099/ijs.0.02873-0.
   Google Scholar
• Kosciow K, Deppenmeier U. Characterization of a phospholipid-regulated β-galactosidase from Akkermansia muciniphila involved in mucin degradation. Microbiologyopen. 2019;8:e796. PMID: 30729732. doi:10.1002/mbo3.796.
   Google Scholar
• Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107–113. PMID: 27892954. doi:10.1038/nm.4236.
   Google Scholar
• Alam A, Leoni G, Quiros M, Wu H, Desai C, Nishio H, Jones RM, Nusrat A, Neish AS. The microenvironment of injured murine gut elicits a local pro-restitutive microbiota. Nat Microbiol. 2016;1(2):15021. PMID: 27571978. doi:10.1038/nmicrobiol.2015.21.
   Google Scholar
• Zhang T, Li Q, Cheng L, Buch H, Zhang F. Akkermansia muciniphila is a promising probiotic. Chin J Nat Med. 2019;17:11. PMID: 31006995. doi:10.1016/S1875-5364(19)30101-3.
   Google Scholar
• Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(40):10713–10718. PMID: 28893978. doi:10.1073/pnas.1711235114.
   Google Scholar
• Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, Kim CH. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015;8(1):80–93. PMID: 24917457. doi:10.1038/mi.2014.44.
   Google Scholar
• Wexler AG, Goodman AL. An insider’s perspective: bacteroides as a window into the microbiome. Nat Microbiol. 2017;2(5):17026. PMID: 28440278. doi:10.1038/nmicrobiol.2017.26.
   Google Scholar
• Rocha ER, Smith CJ. Ferritin-like family proteins in the anaerobe bacteroides fragilis: when an oxygen storm is coming, take your iron to the shelter. Biometals. 2013;26(4):577–591. PMID: 23842847. doi:10.1007/s10534-013-9650-2.
   Google Scholar
• Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hamalainen AM, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165(4):842–853. PMID: 27133167. doi:10.1016/j.cell.2016.04.007.
   Google Scholar
• Chan JL, Wu S, Geis AL, Chan GV, Gomes TAM, Beck SE, Wu X, Fan H, Tam AJ, Chung L, et al. Non-toxigenic bacteroides fragilis (NTBF) administration reduces bacteria-driven chronic colitis and tumor development independent of polysaccharide A. Mucosal Immunol. 2019;12(1):164–177. PMID: 30279518. doi:10.1038/s41385-018-0085-5.
   Google Scholar
• Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4(4):337–349. PMID: 18854238. doi:10.1016/j.chom.2008.09.009.
   Google Scholar
• Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084. PMID: 26541610. doi:10.1126/science.aad1329.
   Google Scholar
• Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1(5):653–661. PMID: 26181352. doi:10.1001/jamaoncol.2015.1377.
   Google Scholar
• Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S, et al. Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–355. PMID: 25680274. doi:10.1016/j.immuni.2015.01.010.
   Google Scholar
• Chen T, Li Q, Wu J, Wu Y, Peng W, Li H, Wang J, Tang X, Peng Y, Fu X. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. Cancer Immunol Immunother. 2018;67(10):1635–1646. PMID: 30121899. doi:10.1007/s00262-018-2233-x.
   Google Scholar
• Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–215. PMID: 23954159. doi:10.1016/j.chom.2013.07.007.
   Google Scholar
• Hamada T, Zhang X, Mima K, Bullman S, Sukawa Y, Nowak JA, Kosumi K, Masugi Y, Twombly TS, Cao Y, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res. 2018;6(11):1327–1336. PMID: 30228205. doi:10.1158/2326-6066.Cir-18-0174.
   Google Scholar
• Lakritz JR, Poutahidis T, Levkovich T, Varian BJ, Ibrahim YM, Chatzigiagkos A, Mirabal S, Alm EJ, Erdman SE. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice. Int J Cancer. 2014;135(3):529–540. PMID: 24382758. doi:10.1002/ijc.28702.
   Google Scholar
• Lenoir M, Del Carmen S, Cortes-Perez NG, Lozano-Ojalvo D, Munoz-Provencio D, Chain F, Langella P, de Moreno de LeBlanc A, LeBlanc JG, Bermudez-Humaran LG. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J Gastroenterol. 2016;51(9):862–873. PMID: 26749362. doi:10.1007/s00535-015-1158-9.
   Google Scholar
• Shen X, Liu L, Peek RM, Acra SA, Moore DJ, Wilson KT, He F, Polk DB, Yan F. Supplementation of p40, a lactobacillus rhamnosus GG-derived protein, in early life promotes epidermal growth factor receptor-dependent intestinal development and long-term health outcomes. Mucosal Immunol. 2018;11(5):1316–1328. PMID: 29875401. doi:10.1038/s41385-018-0034-3.
   Google Scholar
• Makioka Y, Tsukahara T, Ijichi T, Inoue R. Oral supplementation of bifidobacterium longum strain BR-108 alters cecal microbiota by stimulating gut immune system in mice irrespectively of viability. Biosci Biotechnol Biochem. 2018;82(7):1180–1187. PMID: 29557273. doi:10.1080/09168451.2018.1451738.
   Google Scholar
• Laparra JM, Olivares M, Gallina O, Sanz Y, Leulier F. Bifidobacterium longum CECT 7347 modulates immune responses in a gliadin-induced enteropathy animal model. PLoS One. 2012;7(2):e30744. PMID: 22348021. doi:10.1126/science.aah5825.
   Google Scholar